Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations
- 24 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (7), 1710-1713
- https://doi.org/10.1038/s41409-021-01230-z
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL childrenLeukemia, 2020
- Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphomaOncoTargets and Therapy, 2019
- Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cellsBone Marrow Transplantation, 2019
- Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cellsExperimental Hematology, 2018
- Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic LeukemiaClinical Cancer Research, 2017
- De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell RejuvenationCell, 2017
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patientsLeukemia, 2017
- Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the HorseTransplantation and Cellular Therapy, 2016
- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic SyndromeTransplantation and Cellular Therapy, 2015
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013